Minimal disease activity in atopic dermatitis is sustainable at one year in early responders. Discover predictors and ...

Recent evidence indicates that a significant percentage of patients with recalcitrant eczematous dermatitis, including those dubbed "treatment-resistant" to dupilumab (Dupixent), may be living with a ...

A group of dermatologists and dermatology students studied why atopic dermatitis may be related to certain cardiovascular diseases, neuropsychiatric diseases, autoimmune diseases, and obesity. It’s ...

Please provide your email address to receive an email when new articles are posted on . An association between more severe atopic dermatitis and inflammatory bowel disease has been found. These ...

Please provide your email address to receive an email when new articles are posted on . Systemic control of inflammation with upadacitinib may reduce cardiovascular event risk in adults with atopic ...

Daily application of roflumilast cream for 52 weeks improves the signs and symptoms of AD in patients with various comorbid atopic conditions.

A new study in Cell Reports offers fresh evidence that fibroblasts actively shape inflammatory environments in skin disease. Using single-cell RNA sequencing and multiplexed error-robust fluorescence ...

Many eczema patients skip the mental health talk. Learn how to discuss anxiety and depression with your dermatologist to unlock better treatment options and systemic therapies.

Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic ...

NEW YORK — Over the last year, labeling for a number of anti-inflammatory treatments for dermatologic diseases has been updated to include adolescents as well as young children, and this trend is not ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today provided an update on its test ...